Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
Clinical trial NCT01975142 · COMPLETED
Trial details
- NCT number
- NCT01975142
- Sponsor
- Institut Curie
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-11-07
- Primary completion
- 2018-02-13
- Enrollment
- 155
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.